Trial Profile
A Long-term, Randomised, Double-blind, Placebo-controlled, Multinational, Multi-centre Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes (SUSTAIN 6 - Long-term Outcomes)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Nov 2023
Price :
$35
*
At a glance
- Drugs Semaglutide (Primary)
- Indications Cardiovascular disorders; Type 2 diabetes mellitus
- Focus Adverse reactions; Registrational
- Acronyms SUSTAIN-6
- Sponsors Novo Nordisk
- 06 Oct 2023 Results assessing whether retinal oxy-genation, retinal vascular autoregulation, and central retinal thickness (CRT) are altered by semaglutide, empagliflozin or the combination presented at the 59th Annual Meeting of the European Association for the Study of Diabetes.
- 26 Jun 2023 Results using individual-level participant data from LEADER , SUSTAIN 6 and PIONEER 6 , comparing cardiovascular (CV) protective effect of liraglutide vs semaglutide in subjects with type 2 diabetes, presented at the 83rd Annual Scientific Sessions of the American Diabetes Association
- 01 Apr 2023 Results of pooled post hoc analysis (n=6480 from two studies SUSTAIN 6/PIONEER 6) assessing the effects of semaglutide versus placebo on eGFR decline published in the Kidney International